Structural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement.

J Biomol Struct Dyn

Bioinformatics Research Group (BIRG), Department of Biosciences, Faculty of Science, Universiti Teknologi Malaysia, Skudai, Johor, Malaysia.

Published: February 2023

Hepcidin is a principal regulator of iron homeostasis and its dysregulation has been recognised as a causative factor in cancers and iron disorders. The strategy of manipulating the presence of hepcidin peptide has been used for cancer treatment. However, this has demonstrated poor efficiency and has been short-lived in patients. Many studies reported using minihepcidin therapy as an alternative way to treat hepcidin dysregulation, but this was only applied to non-cancer patients. Highly conserved fish hepcidin protein, HepTH1-5, was investigated to determine its potential use in developing a hepcidin replacement for human hepcidin (Hepc25) and as a therapeutic agent by targeting the tumour suppressor protein, p53, through structure-function analysis. The authors found that HepTH1-5 is stably bound to ferroportin, compared to Hepc25, by triggering the ferroportin internalisation via Lys42 and Lys270 ubiquitination, in a similar manner to the Hepc25 activity. Moreover, the residues Ile24 and Gly24, along with copper and zinc ligands, interacted with similar residues, Lys24 and Asp1 of Hepc25, respectively, showing that those molecules are crucial to the hepcidin replacement strategy. HepTH1-5 interacts with p53 and activates its function through phosphorylation. This finding shows that HepTH1-5 might be involved in the apoptosis signalling pathway upon a DNA damage response. This study will be very helpful for understanding the mechanism of the hepcidin replacement and providing insights into the HepTH1-5 peptide as a new target for hepcidin and cancer therapeutics.Communicated by Ramaswamy H. Sarma.

Download full-text PDF

Source
http://dx.doi.org/10.1080/07391102.2021.2011415DOI Listing

Publication Analysis

Top Keywords

hepcidin replacement
16
hepcidin
10
hepth1-5 peptide
8
hepth1-5
6
structural functional
4
functional characterisation
4
characterisation hepth1-5
4
peptide potential
4
potential hepcidin
4
replacement
4

Similar Publications

Comparative analysis of oral iron therapy regimens in premenopausal women with iron deficiency anemia.

Sci Rep

December 2024

Department of Internal Medicine, Istanbul Medeniyet University, Fahrettin Kerim Gokay Street, Kadikoy, 34722, Istanbul, Turkey.

Iron deficiency anemia (IDA) is prevalent among women of reproductive age. Treatment aims to replenish iron stores and normalize hemoglobin levels, with oral iron therapy being the preferred route in most cases. This study aimed to compare the efficacy and side effects of three common oral treatment regimens in premenopausal women with IDA.

View Article and Find Full Text PDF

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.

Hematology Am Soc Hematol Educ Program

December 2024

Medical and Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN.

Anemia is a hallmark of chronic kidney disease (CKD), worsens with disease progression, and profoundly affects a patient's well-being. Major pathogenic factors are inadequate kidney erythropoietin (EPO) production and absolute and functional iron deficiency. The 2 mainstays of current anemia treatment are a) replacement therapy with recombinant EPO or 1 of its glycosylated derivatives, administered subcutaneously or intravenously, and b) intravenous (IV) iron injections.

View Article and Find Full Text PDF

Translating evidence into practice: Managing electrolyte imbalances and iron deficiency in heart failure.

Eur J Intern Med

January 2025

Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Lower Saxony, Germany. Electronic address:

Article Synopsis
  • Mineral abnormalities, including dyskalaemia, hyponatraemia, hypomagnesaemia, and iron deficiency, are common in heart failure (HF) and are linked to worse health outcomes and increased mortality rates.
  • The imbalance in these minerals is influenced by factors like neurohumoral activation, effects of HF medications, and chronic conditions like kidney disease.
  • Iron deficiency, affecting up to 60% of HF patients, is particularly serious, but iron replacement therapy has shown benefits, especially in patients with reduced and preserved ejection fractions.
View Article and Find Full Text PDF

Enzyme replacement therapy improves erythropoiesis and iron dysregulation in Gaucher disease.

Ann Hematol

December 2024

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Medicina ad Indirizzo Metabolico, Via Francesco Sforza 35, Milan, 20122, Italy.

Article Synopsis
  • Anemia and hyperferritinemia are common at the onset of Gaucher disease, affecting 41% and 51% of patients respectively.
  • Over a 5-year period, enzyme replacement therapy (ERT) significantly improved hemoglobin levels, decreased markers of ineffective erythropoiesis, and reduced serum ferritin, indicating better iron metabolism.
  • The study highlights the important role of iron dysregulation in anemia for Gaucher disease patients and shows that ERT enhances both erythropoiesis and iron handling.
View Article and Find Full Text PDF

Decreased testosterone levels are often under-recognized as a cause of anemia in males with hypogonadism. Men, as a subset, are less likely to seek medical care, especially those who struggle with complex psychiatric and social conditions, where they may lack full autonomy. Increasing testosterone levels leads to erythrocytosis by elevating erythropoietin and soluble transferrin receptor levels and suppressing hepcidin and ferritin levels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!